GT Apeiron Therapeutics

China
Shaxi, Fujian, China

Company profile

GT Apeiron Therapeutics company profile

GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2019-01-01, Year

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$44.5M
Last funding
Series A / $17.5M / 2022-03-29
Last equity funding
Series A / $17.5M
Investors
3
Lead investors
2
Founders
1
Articles
6

Founders and investors

Founders

Alan Au

Lead investors

GT Healthcare Capital PartnersPanacea Venture

Investors

GT Healthcare Capital PartnersPanacea VentureViva BioInnovator